Clinical Trial

Validation of French PHQ-4 and PC-PTSD-5 Screening Scales

Study acronym: DEPSYSTAGE
Recruiting
View on ClinicalTrials.gov →
Summary
Mental illness is a major public health issue. It affects one in five people, represents the largest expense for health insurance (14%), is the leading cause of years lived with disability, and suicide is the main cause of death among people aged 15 to 35. Depression affects 15 to 20% of individuals at some point in their lives. Trauma-related disorders affect 4.6% of people, including 1- 2% with post-traumatic stress disorder (PTSD). Screening for mental health problems in primary care is crucial. It enables doctors to provide early treatment, reduces the need for emergency care, and decreases both the number and duration of hospital stays. However, general practitioners and other non-mental health professionals often report lacking the time, training, and tools to conduct such screenings. Fortunately, brief and validated screening tools exist in English: The PHQ-4 (Patient Health Questionnaire-4) for anxiety and depression, and the PC-PTSD-5 (Primary Care PTSD Screen for DSM-5) for PTSD. So far, no French versions of these tools have been validated.
Trial Details
NCT Number NCT07396623
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Mental Illness
Enrollment 90 participants
Start Date 2026-01-26
Primary Completion 2027-08-15 (estimated)
Study Completion 2027-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-09